Brexanolone

Sage Therapeutics' lead therapeutic asset, dalzanemdor, failed a Phase II trial for Huntington's disease, leading to discontinuation of its development. This marks the third mid-stage failure for the company, which has seen its stock value drop by over 90% in the past year and a half. Sage's pipeline is now limited, with only one commercial product, Zurzuvae, generating revenue. The company has undergone significant restructuring and layoffs to focus on Zurzuvae's commercialization, but its path to profitability remains uncertain.

Terray Therapeutics enhances AI platform tNova for small molecule solutions; Kailera Therapeutics launches with $400M Series A for obesity treatments; Seaport Therapeutics raises $225M Series B for bioavailability and hepatotoxicity reduction; Aktis Oncology secures $175M Series B for radiopharmaceuticals; Alpha-9 Oncology raises $126.3M Series C for radiopharmaceuticals; Terray Therapeutics closes $120M Series B for AI platform; Triveni Bio raises $115M Series B for monoclonal antibody inhibitor and pancreatitis treatment; Purespring Therapeutics secures $105M Series B for kidney disease; Inventiva receives $101.5M financing for Phase 3 trial of metabolic dysfunction-associated steatohepatitis; Cytovale raises $100M Series D for sepsis diagnostic test; Judo Bio launches with $100M Series A for oligonucleotide medicines for the kidney; Resolution Therapeutics raises $82.4M Series B for end-stage liver disease therapy; Nuclera completes $75M financing for protein expression system; Nura Bio raises $68M Series A for brain-penetrant SARM1 inhibitor; Basecamp Research secures $60M Series B for data collection and AI development; Constructive Bio raises $58M Series A for custom genomic writing technology; Genespire closes $52M Series B for methylmalonic acidemia clinical trial; 858 Therapeutics raises $50M Series B for small molecule therapeutics; LoQus23 secures $43M Series A for allosteric small molecule MutSβ inhibitor; Arda Therapeutics gains $43M Series A for targeted cell depletion therapies; Enara Bio raises $32.5M Series B for TCR-based immunotherapies; MarchBio receives $28.4M Series A for CAR-T cell therapy; Phare Bio and Collins Lab awarded $27M for AI discovery platform and novel antibiotics; Alyssum Therapeutics raises $26M Series A for first-in-class small molecule CMTR2 inhibitor; Passkey Therapeutics emerges with $20M seed funding for complex disease therapies; Lymphatica Medtech SA raises $19.3M Series B for novel lymphedema treatment; MARAbio closes $19M Series A for blood test for autism diagnosis; Tolerance Bio secures $17.2M seed financing for thymus-based therapies; Shift Bioscience raises $16M seed funding for cell simulation AI platform; Mindpeak raises $15.3M Series A for commercialization of clinical diagnostic AI; C2N Diagnostics receives $15M financing for next-gen tests for tau tangle pathology; Booster Therapeutics launches with $15M financing for small molecule discovery platform; LIfT BioSciences raises $12.9M Series A for first-in-class allogeneic innate cell therapy; PhoreMost adds $12M to Series B for novel degrader programs; Sequentia Biotech closes $10.8M Series A for bioinformatics platform expansion.

Various biotech companies announced significant funding rounds for advancing next-gen therapies, diagnostic tests, and AI platforms, including Kailera Therapeutics for obesity treatments, Seaport Therapeutics for bioavailability enhancements, Aktis Oncology for radiopharmaceuticals, Alpha-9 Oncology for radiopharmaceuticals, Terray Therapeutics for AI-driven small molecule solutions, Triveni Bio for monoclonal antibody inhibitors, Purespring Therapeutics for kidney disease treatments, Inventiva for metabolic dysfunction-associated steatohepatitis, Cytovale for sepsis diagnostic tests, Judo Bio for oligonucleotide medicines, Resolution Therapeutics for end-stage liver disease therapies, Nuclera for protein expression systems, Nura Bio for brain-penetrant SARM1 inhibitors, Basecamp Research for programmable genetic medicines, Constructive Bio for custom genomic writing technology, Genespire for methylmalonic acidemia treatments, 858 Therapeutics for small molecule therapeutics, LoQus23 for allosteric small molecule MutSβ inhibitors, Arda Therapeutics for targeted cell depletion therapies, Enara Bio for TCR-based immunotherapies, MarchBio for CAR-T cell therapies, Phare Bio for AI-driven antibiotic discovery, Alyssum Therapeutics for CMTR2 inhibitors, Passkey Therapeutics for complex disease therapies, Lymphatica Medtech for lymphedema treatments, MARAbio for autism diagnosis, Tolerance Bio for thymus-based therapies, Shift Bioscience for cell simulation AI, Mindpeak for clinical diagnostic AI, C2N Diagnostics for tau tangle pathology tests, Booster Therapeutics for small molecule discovery, LIfT BioSciences for allogeneic innate cell therapies, PhoreMost for novel degrader programs, and Sequentia Biotech for bioinformatics platform expansion.

Seaport Therapeutics raised $225 million to advance its lead drug candidate for depression, leveraging its Glyph technology platform. The company aims to advance its pipeline through clinical milestones and further develop its Glyph technology.

Seaport Therapeutics, a biotech developing brain drugs, raised $225 million from healthcare investors. Founded by PureTech Health, Seaport aims to create psychiatry medicines with fewer side effects. The company's most advanced program is an oral drug targeting major depressive disorder, with additional compounds for generalized anxiety disorder and neuropsychiatric conditions. Seaport plans to use the funds to advance clinical research and its 'Glyph' drugmaking technology.

Seaport Therapeutics closed a $225 million Series B financing round, led by General Atlantic, to advance its neuropsychiatric medicines and Glyph™ technology platform. The Glyph platform enhances oral drug administration via the lymphatic system, addressing issues like low bioavailability and side effects. The funding will support clinical trials for candidates like SPT-300 for major depressive disorder and SPT-320 for generalized anxiety disorder.

Seaport Therapeutics, a PureTech Health founded entity, closed a $225 million oversubscribed Series B financing round led by General Atlantic, to support its pipeline of first and best-in-class neuropsychiatric medicines.